Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 9, 2022PlateletsOpen Access

Inhibition of Src but not Syk causes weak reversal of GPVI-mediated platelet aggregation measured by light transmission aggregometry

View Full Paper
Ask AI
Bookmark
Share

Key result

Inhibition of Src kinase caused a weak (~10%) reversal in GPVI-mediated platelet aggregation, whereas inhibition of Syk or Btk did not.

Why the study?

Src tyrosine kinases and Syk contribute to sustained platelet aggregation under arterial shear, but whether they are required for aggregation under minimal shear following GPVI or CLEC-2 activation was unknown.

Population

Platelet suspensions activated by CRP or rhodocytin

Comparison

Inhibition of Src vs Syk vs Btk

Design

In vitro experimental study

Follow-up

Up to 50 min

Authors

HCHilaire Yam Fung CheungLMLuis A. MoránASAlbert Sickmann

Discussion

Loading...

Member takes

Overview

Src inhibition modestly reverses aggregation in this model; hypothesis-generating for pathway-specific antithrombotics, requiring human validation.

Structured PICO

P
Population
Platelet suspension (in vitro model)
I
Intervention
Inhibitors of Src, Syk or Bruton's tyrosine kinase (Btk) added at 150 sec post-activation
O
Outcome
Reversal of platelet aggregation measured by light transmission aggregometry (LTA)surrogate

Src kinase, but not Syk or Btk, plays a role in sustaining GPVI-mediated platelet aggregation under minimal shear conditions.

Cite This Study

Cheung et al. (2022) studied Platelet aggregation. Src, Syk, and Btk inhibitors was evaluated on Reversal of platelet aggregation measured by light transmission aggregometry. Inhibition of Src kinase caused a weak (~10%) reversal in GPVI-mediated platelet aggregation, whereas inhibition of Syk or Btk did not.

synapsesocial.com/papers/6a898ca80e1a8f7244fd4d2fhttps://doi.org/10.1080/09537104.2022.2069235
View Full Paper
Ask AI
Bookmark
Share